- Policy
- Lupus drug 'BENLYSTA' opened rehabilitation path
- by Lee, Tak-Sun Nov 29, 2019 06:33am
- There is now a way to recover the lupus drug, Benlysta, which is at risk of withdrawal due to failure to meet postmarketing (PMS) criteria. The MFDS decided to use the drug as a RMP (Risk Management Plan) after long discussion of the Central Pharmaceutical Affairs Council and continue to use it for patients to monitor side effects. Acco
- Company
- PPC signs MOU with Clinerion to shorten clinical period
- by Eo, Yun-Ho Nov 29, 2019 06:32am
- Asia-specific CRO PPC (Protech Pharmaservices Corporation) recently signed an MOU with Clinerion, Switzerland, to shorten the time for clinical institution selection and patient registration. Through this partnership, PPC expects to use Clinerion's Patient Network Explorer platform to accelerate enrollment of subjects in global clinical tr
- Company
- Lynparza tablet requests for expanded reimbursement
- by Eo, Yun-Ho Nov 29, 2019 06:31am
- Anticancer treatment Lynparza is applying for insurance reimbursement on its orally taken tablet formulation. Pharmaceutical industry source tells AstraZeneca Korea has recently submitted reimbursement application for extended indication of a poly ADP ribose polymerase (PARP) inhibitor Lynparza (olaparib). The anticancer treatment is now
- Policy
- Dantrolene designated as emergency drug at KRW 95K
- by Kim, Jung-Ju Nov 28, 2019 09:39pm
- 20 mg injection of Dantrolen, used for malignant hyperthermia and neuroleptic malignant syndrome (NMS), was designated as an emergency treatment and its insurance reimbursed price would be maintained at around 95,000 won. According to pharmaceutical industry source on Nov. 26, Ministry of Health and Welfare (MOHW) is planning to update t
- Company
- GLP-1 diabetes, Trulicity runs at a high speed
- by An, Kyung-Jin Nov 28, 2019 10:45am
- Once-weekly diabetes treatment, Trulicity, overwhelms the GLP-1 analog market. The company's annual sales are over &8361;30 billion, exceeding &8361;27 billion in nine months. The market grew to more than 98% with a single item, increasing the overall market size. According to the drug market research agency IQVIA on the 28th, Trulicit
- Company
- BMS-Celgene Korea promotes Kim Jinyoung as new CEO
- by Eo, Yun-Ho Nov 28, 2019 10:19am
- The decision has been made and it was a promotion from within. Kim Jinyoung (43), a former acting CEO, was appointed as the CEO of merged BMS-Celgene Korea. Kim used to serve as a Head of Legal and Compliance in BMS Korea, but was appointed as an acting CEO after former President Park Hye-sun (49) left the office. Kim had been active as
- Company
- Ildong great likelihood to sell strongly 'Otrivin' by GSK
- by Jung, Hye-Jin Nov 28, 2019 06:14am
- Ildong pharmaceuticals has the most potential of otc vendor for 10 GSK items. It is possible that A distributor, Zuellig Pharma Korea will be charge of selling Lamisil. According to the industry on the 26th, GSK, Ildong Pharmaceuticals and Zuellig Pharma Korea are in the last negotiations over the right to sell 10 generic drugs. A
- Company
- MA experts admit headquarters’ “Korea Passing” orders
- by Kim, Jin-Gu Nov 28, 2019 06:14am
- With one phenomenon, there are two interpretations. The government and pharmaceutical industry are showing polarizing views on the current situation and the cause of Korea Passing phenomenon. As if they are speaking in different languages, their prospective and proposed solutions are like parallel lines never crossing each other’s path.
- Company
- Inflximab injection ‘Remsima SC’ good to go in EU
- by Lee, Seok-Jun Nov 27, 2019 11:06pm
- On Nov. 26, Celltrion announced its hypodermic injection Remsima SC got the green light from European authority. The injection was approved on indication of rheumatoid arthritis in 120 mg dose. Remsima SC is the first subcutaneous formulation of inflximab to have passed by the European regulator. Remsima SC would be available in 31 Europ
- Policy
- Gazyva applied Moon Care policy’s selective health benefits
- by Lee, Hye-Kyung Nov 27, 2019 11:06pm
- Roche's Gazyva(Obinutuzumab), a non-Hodgkin's lymphoma treatment, will be converted into a selective reimbursement benefit in accordance with Moon Jae-in Care's ‘Non-benefit’ policy. The implementation date is December 15. The Korea Health Insurance Review and Assessment Service announced that it would revise the details of the criteria
